title: EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
abstract: BACKGROUND
  (32)P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom (32)P is the most optimal treatment option, an assertion supported by two large studies with long follow-up.
  
  
  OBJECTIVE
  The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for (32)P phosphate therapy.
authors.affiliation: Department of Oncology, Lund University Hospital, 221 85 Lund, Sweden. Jan.Tennvall@med.lu.se
authors.forename: Jan
authors.initials: J
authors.lastname: Tennvall
authors.forename: Boudewijn
authors.initials: B
authors.lastname: Brans
mesh_terms: D000328:Adult; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000532:radiotherapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D011786:Quality Control; D011874:Radiometry; D019275:Radiopharmaceuticals; D011878:Radiotherapy / Q000379:methods* / Q000592:standards*; D013920:Thrombocythemia, Essential / Q000532:radiotherapy*
chemical_list: D010761:Phosphorus Radioisotopes; D019275:Radiopharmaceuticals